Daily pill shows early promise against pancreatic cancer
SingTao · 1 SOURCESabout 1 hour ago2 MIN

Summary
A US-led early-stage clinical trial has reported encouraging results for daraxonrasib, a once-daily targeted pill used with chemotherapy in previously untreated patients with metastatic pancreatic cancer. The phase one and two study, led by Memorial Sloan Kettering Cancer Center in New York and presented on Friday at a European cancer research meeting in Barcelona, enrolled 61 patients. Researchers said 60.7% of patients saw their tumours shrink or disappear, while 8.2% achieved a complete response with no tumour visible on scans. Outside experts welcomed the data as a major advance, but cautioned that the study was small and lacked a chemotherapy-only control group
Key Points
- The trial tested 200mg of oral daraxonrasib taken daily alongside regular injections of two chemotherapy drugs in 61 untreated metastatic pancreatic cancer patients
- Researchers reported a 60.7% tumour response rate, and 8.2% of patients reached complete remission with no tumour seen on scans
- Including patients whose disease did not worsen, the overall disease control rate reached 90.2% in the phase one and two study
- Median progression-free survival was 12.8 months, while the one-year overall survival rate was 76.6%, according to the trial data
- Study leader Wungki Park said the team was surprised to see tumours disappear on scans after decades of only modest survival gains
Why It Matters
For Hong Kong readers, the findings matter because pancreatic cancer is the city’s fourth deadliest cancer, and many patients are diagnosed only after the disease has spread. Standard chemotherapy for metastatic disease typically sees tumours regrow after five to six months, with overall survival of only eight to 11 months, so any treatment that extends control beyond a year could alter expectations for first-line care. Even so, experts warned it is too early to call the pill a cure, because scans can miss residual disease and relapses remain possible